Ignite Creation Date:
2025-12-24 @ 6:42 PM
Ignite Modification Date:
2026-01-31 @ 7:57 PM
Study NCT ID:
NCT05530057
Status:
RECRUITING
Last Update Posted:
2025-11-20
First Post:
2022-09-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer
Sponsor:
Organization: